Tempus AI, Inc. TEM
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About TEM
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Tempus AI, Inc. is a healthcare technology and precision medicine company focused on applying artificial intelligence, clinical data analytics, and molecular diagnostics to improve patient care and therapeutic development. The company operates primarily in the oncology sector but has expanded into adjacent areas including cardiology, radiology, infectious disease, and mental health. Tempus combines multimodal healthcare data—including genomic sequencing, clinical records, imaging, and laboratory information—with AI-enabled software tools to support physicians, researchers, and life sciences companies.
The company’s primary revenue drivers include genomic testing services, data licensing and analytics for pharmaceutical and biotechnology companies, and AI-enabled clinical software platforms. Tempus serves healthcare providers, academic medical centers, biopharmaceutical companies, and researchers. Its strategic positioning is rooted in the scale of its proprietary clinical and molecular data platform, integration of AI capabilities into clinical workflows, and relationships with major health systems and drug developers. Founded in 2015 by Eric Lefkofsky, Tempus evolved from an oncology-focused precision medicine company into a broader AI-enabled healthcare infrastructure platform, culminating in its public listing on Nasdaq under the ticker TEM in 2024.
Business Operations
Tempus organizes its operations around diagnostic testing, data and analytics, and AI-enabled software solutions. Its core activities include next-generation sequencing (NGS) testing, molecular profiling, clinical trial matching, and AI-driven decision support tools. Revenue is generated through laboratory testing reimbursement, contracts with life sciences customers, data licensing arrangements, and software subscriptions. The company’s principal operating capabilities are supported by proprietary datasets integrating de-identified clinical, genomic, transcriptomic, and imaging information.
The company operates primarily in the United States but maintains collaborations and commercial relationships internationally. Tempus controls laboratory infrastructure, AI and machine learning technologies, and a large multimodal healthcare data platform used for drug discovery and clinical research applications. Key subsidiaries and business assets include Tempus Labs, Tempus Next, and acquired businesses such as Ambry Genetics and AKASA integrations and partnerships referenced in public disclosures and investor materials. Tempus also collaborates with pharmaceutical manufacturers, healthcare systems, and academic institutions to support biomarker discovery, clinical trial enrollment, and precision therapeutics development.
Strategic Position & Investments
Tempus has pursued a growth strategy centered on expanding its AI-enabled healthcare platform, increasing the scale of its clinical and molecular datasets, and broadening its diagnostic and software offerings. Major strategic initiatives include expansion into additional disease categories beyond oncology, development of generative AI and clinical workflow automation tools, and strengthening its life sciences partnerships. The company has also invested heavily in infrastructure supporting data interoperability, computational biology, and machine learning applications for healthcare providers and pharmaceutical companies.
A significant component of Tempus’s strategic positioning has involved acquisitions and investments intended to deepen diagnostic and data capabilities. The acquisition of Ambry Genetics materially expanded Tempus’s hereditary testing and genetic screening portfolio. The company has also invested in AI-assisted healthcare technologies and clinical software platforms intended to improve operational efficiency and physician decision-making. Tempus remains active in emerging healthcare AI sectors including multimodal foundation models, clinical language models, personalized therapeutics, and real-world evidence analytics used in drug development and commercialization.
Geographic Footprint
Tempus is headquartered in Chicago, Illinois, and maintains operational and commercial activities across major healthcare markets in the United States. Its laboratory, technology, and commercial operations support relationships with hospitals, academic medical centers, and pharmaceutical companies nationwide. The company’s primary revenue base remains concentrated in the U.S. healthcare and life sciences sectors.
Internationally, Tempus has expanded through partnerships, research collaborations, and biopharmaceutical engagements spanning Europe, Asia-Pacific, and other global markets. Its data analytics and life sciences offerings support multinational pharmaceutical research programs and clinical development initiatives. While the company’s operational footprint outside the United States is smaller relative to domestic operations, its datasets and AI capabilities have increasing international relevance in precision medicine and drug discovery ecosystems.
Leadership & Governance
Tempus was founded by Eric Lefkofsky, a technology entrepreneur known for founding and leading several data and technology companies. The company’s leadership strategy emphasizes integrating AI into clinical workflows, scaling real-world healthcare data infrastructure, and accelerating precision medicine adoption. Public filings and investor communications consistently describe the company’s vision as creating an intelligent operating system for healthcare built on multimodal data and machine learning capabilities.
Key executives include:
- Eric Lefkofsky – Founder and Chief Executive Officer
- Jim Rogers – Chief Financial Officer
- Ryan Fukushima – Chief Operating Officer
- Ezra Cohen, M.D. – Chief Medical Officer, Oncology
- Kate Sasser – Chief Strategy Officer
- Terron Bruner – Chief Commercial Officer
The company operates under a board governance structure typical of publicly traded U.S. healthcare technology companies, with oversight responsibilities related to compliance, financial reporting, data governance, cybersecurity, and strategic growth initiatives. Public disclosures indicate that management prioritizes long-term investment in AI infrastructure, regulated diagnostic capabilities, and partnerships with healthcare and life sciences organizations.